Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

June 11, 2020

Study Completion Date

June 11, 2020

Conditions
Bladder Cancer
Interventions
DRUG

MPDL3280A

Intravenous infusion

Trial Locations (20)

Unknown

Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux

Hospices Civils de Lyon, Lyon

Institut Paoli-Calmettes, Marseille

Institut Claudius Régaud, Toulouse

Netherlands Cancer Institute (NKI), Amsterdam

Athaia Xarxa Manresa, Barcelona

Hospital del Mar, Barcelona

Hospital Germans Trias i Pujol, Barcelona

Hospital Santa Creu i Sant Pau, Barcelona

Hospital Vall d'Hebron, Barcelona

Hospital Reina Sofía, Córdoba

Hospital 12 de Octubre, Madrid

CHU de Santiago, Santiago de Compostela

Hospital Virgen del Rocío, Seville

Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

Barts Health NHS Trust, London

University College London Hospitals NHS Foundation Trust, London

Oxford University Hospitals NHS Foundation Trust, Oxford

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Queen Mary University of London

OTHER

NCT02662309 - Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder | Biotech Hunter | Biotech Hunter